Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, recently hosted a Key Opinion Leader (KOL) Breakfast for healthcare investors and industry professionals at the NY Palace Hotel. A complete video of this event, as well as brief highlights from the presentations are available and posted for viewing at

The panelists discussed the dire need for new therapies for older patients with hematologic malignancies including acute myeloid leukemia (AML), and the curative role of bone marrow transplant. Iomab-B was described as having efficacy and safety superior to that of traditional myeloablative regimens, and likely to markedly increase the number of patients eligible for transplant. An update on the upcoming Phase 3 clinical trial of Iomab-B, plus clinical positioning and positive commercial prospects were also provided, and can be viewed online.

The meeting featured bone marrow transplant and hematology specialist Hillard M. Lazarus, MD, a Professor of Medicine at Case Western Reserve University (CWRU) School of Medicine, as well as Disease Team Leader and Director of Novel Cell Therapy at University Hospitals, Case Medical Center, and Company Scientific Advisory Board Member. Also featured was radiopharmaceutical industry veteran Roland U. Turck, MD, Managing Partner at TurckBio and recently-appointed Senior Advisor to the Actinium Board of Directors. Dr. Turck has extensive, unparalleled experience in the launch and commercialization of radiopharmaceuticals.

Dr. Lazarus performed the first bone marrow transplant in Ohio in 1976, and has had a seminal impact on multiple aspects of transplantation He now heads several clinical trials at the National Center for Regenerative Medicine (CWRU). He has over 500 publications and has won a variety of lifetime achievement, distinguished alumnus, and cancer research awards, in addition to fellowships sponsored by the Leukemia Society of America and the American Cancer Society.

Dr. Turck was formerly the head of Bayer’s Global Specialty Medicine business, where he helped lead the commercialization of Xofigo, the first alpha particle-emitting radioactive agent, whose launch has been the most commercially successful of any radiopharmaceutical product to date. He is an expert in biopharmaceutical specialty medicine with more than 20 years of pharmaceutical industry experience at Bayer, Berlex, and Schering, having developed and commercialized several major oncology products on a global scale, including Xofigo, Stivarga, Nexavar, and Campath. Original Source)

Shares of Actinium Pharmaceuticals closed last Friday at $2.89. ATNM has a 1-year high of $13.70 and a 1-year low of $2.31. The stock’s 50-day moving average is $2.79 and its 200-day moving average is $4.19.

On the ratings front, MLV & Co. analyst Arlinda Lee reiterated a Buy rating on ATNM, with a price target of $15, in a report issued on March 17. The current price target implies an upside of 419.0% from current levels. According to, Lee has a total average return of -0.6%, a 50.0% success rate, and is ranked #2834 out of 3608 analysts.

Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.